ANI Pharmaceuticals Announces Launch of Vancomycin Capsules
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy
November 4, 2015 8:13 AM ESTRoth Capital maintained a Buy rating on ANI Pharmaceuticals (NASDAQ: ANIP), and cut the price target to $56.00 (from $60.00), following the company's 3Q15 earnings report. ANIP reported 3Q15 revenues of $20 million, which trailed consensus of $21.4M. The downside appeared to come from non-core branded revenues. Management... More
ANI Pharma (ANIP) Announces U.S. Launch of Generic Vancocin Caps
November 2, 2015 8:22 AM ESTANI Pharma (NASDAQ: ANIP) announced the launch of Vancomycin HCl 125mg and 250mg capsules indicated for treatment of C. difficile-associated diarrhea. The overall US market for Vancomycin HCl Capsules is approximately $113 million, per IMS Health.
Arthur S. Przybyl, President and Chief... More
